Clozapine reverses phencyclidine-induced desynchronization of prefrontal cortex through a 5-HT 1A receptor-dependent mechanism

Neuropsychopharmacology

Volumn 37, Issue 3, 2012, Pages 723-733

  Kargieman, Lucila ^a,b   Riga, Maurizio S ^a,b   Artigas, Francesc ^a,b   Celada, Pau ^a,b  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

Author keywords

5 HT1A receptors; 5 HT2A receptors; antipsychotics; NMDA receptor antagonists; prefrontal cortex; slow cortical oscillations

Indexed keywords

CLOZAPINE; PHENCYCLIDINE; SEROTONIN 1A RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; MALE; MOUSE; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL;

ANIMALS; CLOZAPINE; EXCITATORY AMINO ACID ANTAGONISTS; MICE; MICE, KNOCKOUT; NEURONS; PHENCYCLIDINE; PIPERAZINES; PREFRONTAL CORTEX; PYRIDINES; RECEPTOR, SEROTONIN, 5-HT1A; RECEPTOR, SEROTONIN, 5-HT2A; SEROTONIN ANTAGONISTS;

EID: 84855906680     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2011.249     Document Type: Article

References (97)

1. Allen RM, Young SJ (1978). Phencyclidine-induced psychosis. Am J Psychiatry 135:1081-1084. (Pubitemid 8395441)
2. Amargos-Bosch M, Bortolozzi A, Puig MV, Serrats J, Adell A, Celada P et al (2004). Co-expression and in vivo interaction of serotonin (1A) and serotonin (2A) receptors in pyramidal neurons of prefrontal cortex. Cereb Cortex 14:281-299. (Pubitemid 38252721)
3. Amargos-Bosch M, Lopez-Gil X, Artigas F, Adell A (2006). Clozapine and olanzapine, but not haloperidol, suppress serotonin efflux in the medial prefrontal cortex elicited by phencyclidine and ketamine. Int J Neuropsychopharmcol 9:565-573. (Pubitemid 44607209)
4. Araneda R, Andrade R (1991). 5-Hydroxytryptamine2 and 5-hydroxytryptamine 1A receptors mediate opposing responses on membrane excitability in rat association cortex. Neuroscience 40:399-412.
5. Arnt J, Skarsfeldt T (1998). Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology 18:63-101. (Pubitemid 28026679)
6. Bakker C, Amini F (1961). Observations on the psychotomimetic effects of sernyl. Compr Psychiatry 2:269-280.
7. Basar-Eroglu C, Schmiedt-Fehr C, Mathes B, Zimmermann J, Brand A (2009). Are oscillatory brain responses generally reduced in schizophrenia during long sustained attentional processing? Int J Psychophysiol 71:75-83.
8. Bortolozzi A, Diaz-Mataix L, Toth M, Celada P, Artigas F (2007). In vivo actions of aripiprazole on serotonergic and dopaminergic systems in rodent brain. Psychopharmacology (Berl) 191:745-758. (Pubitemid 46355906)
9. Bortolozzi A, Masana M, Díaz-Mataix L, Cortés R, Scorza MC, Gingrich JA et al (2010). Dopamine release induced by atypical antipsychotics in prefrontal cortex requires 5-HT (1A) receptors but not 5-HT (2A) receptors. Int J Neuropsychopharmacol 13:1299-1314.
10. Bradford AM, Savage KM, Jones DN, Kalinichev M (2010). Validation and pharmacological characterisation of MK-801-induced locomotor hyperactivity in BALB/C mice as an assay for detection of novel antipsychotics. Psychopharmacology (Berl) 212:155-170.
11. Bymaster FP, Calligaro DO, Falcone JF, Marsh RD, Moore NA, Tye NC et al (1996). Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 14:87-96. (Pubitemid 26053226)
12. Castellani S, Giannini AJ, Boeringa JA, Adams PM (1982). Phencyclidine intoxication: assessment of possible antidotes. J Toxicol Clin Toxicol 19:313-319. (Pubitemid 12005389)
13. Celada P, Puig MV, Diaz-Mataix L, Artigas F (2008). The hallucinogen DOI reduces low-frequency oscillations in rat prefrontal cortex: reversal by antipsychotic drugs. Biol Psychiatry 64:392-400.
14. Chou YH, Halldin C, Farde L (2003). Occupancy of 5-HT1A receptors by clozapine in the primate brain: a PET study. Psychopharmacology (Berl) 166:234-240. (Pubitemid 36384769)
15. Contreras D, Steriade M (1995). Cellular basis of EEG slow rhythms: a study of dynamic corticothalamic relationships. J Neurosci 15:604-622.
16. Cossart R, Aronov D, Yuste R (2003). Attractor dynamics of network UP states in the neocortex. Nature 423:283-288. (Pubitemid 40852697)
17. Destexhe A, Hughes SW, Rudolph M, Crunelli V (2007). Are corticothalamic 'up' states fragments of wakefulness? Trends Neurosci 30:334-342. (Pubitemid 46991116)
18. Diaz-Mataix L, Scorza MC, Bortolozzi A, Toth M, Celada P, Artigas F (2005). Involvement of 5-HT1A receptors in prefrontal cortex in the modulation of dopaminergic activity: role in atypical antipsychotic action. J Neurosci 25:10831-10843. (Pubitemid 41692613)
19. Duvvuri V, Risbrough VB, Kaye WH, Geyer MA (2009). 5-HT1A receptor activation is necessary for 5-MeODMT-dependent potentiation of feeding inhibition. Pharmacol Biochem Behav 93:349-353.
20. Elvevag B, Goldberg TE (2000). Cognitive impairment in schizophrenia is the core of the disorder. Crit Rev Neurobiol 14:1-21. (Pubitemid 32193047)
21. Engel AK, Fries P, Singer W (2001). Dynamic predictions: oscillations and synchrony in top-down processing. Nat Rev Neurosci 2:704-716. (Pubitemid 33674816)
22. Engel AK, Singer W (2001). Temporal binding and the neural correlates of sensory awareness. Trends Cogn Sci 5:16-25. (Pubitemid 32063335)
23. Fiorica-Howells E, Hen R, Gingrich J, Li Z, Gershon MD (2002). 5-HT (2A) receptors: location and functional analysis in intestines of wild-type and 5-HT (2A) knockout mice. Am J Physiol Gastrointest Liver Physiol 282:G877-G893. (Pubitemid 34651633)
24. Ford JM, Krystal JH, Mathalon DH (2007). Neural synchrony in schizophrenia: from networks to new treatments. Schizophr Bull 33:848-852. (Pubitemid 47216662)
25. Franklin KBJ, Paxinos G (1997). The Mouse Brain in Stereotaxic. Academic Press: San Diego, CA.
26. Fuster JM (1997). The Prefrontal Cortex. Anatomy, Physiology, and Neuropsychology of the Frontal Lobe. Lipincott-Raven: Philadelphia, New York.
27. Geyer MA, Krebs-Thomson K, Braff DL, Swerdlow NR (2001). Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology 156:117-154. (Pubitemid 32702206)
28. Gleason SD, Shannon HE (1997). Blockade of phencyclidineinduced hyperlocomotion by olanzapine, clozapine and serotonin receptor subtype selective antagonists in mice. Psychopharmacology (Berl) 129:79-84. (Pubitemid 27037454)
29. Goldman-Rakic PS (1994). Working memory dysfunction in schizophrenia. J Neuropsychiatry Clin Neurosci 6:348-357. (Pubitemid 24344855)
30. Gonzalez-Burgos G, Lewis DA (2008). GABA neurons and the mechanisms of network oscillations: implications for understanding cortical dysfunction in schizophrenia. Schizophr Bull 34:944-961.
31. Handelmann GE, Contreras PC, O'Donohue TL (1987). Selective memory impairment by phencyclidine in rats. Eur J Pharmacol 140:69-73. (Pubitemid 17133747)
32. Harrison PJ (1999). The neuropathology of schizophrenia. A critical review of the data and their interpretation. Brain 122:593-624. (Pubitemid 29158770)
33. Homayoun H, Moghaddam B (2007). NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons. J Neurosci 27:11496-11500. (Pubitemid 350006886)
34. Hudzik TJ, Wenger GR (1993). Effects of drugs of abuse and cholinergic agents on delayed matching-to-sample responding in the squirrel monkey. J Pharmacol Exp Ther 265:120-127. (Pubitemid 23320951)
35. Ichikawa J, Ishii H, Bonaccorso S, Fowler WL, O'Laughlin IA, Meltzer HY (2001). 5-HT (2A) and D (2) receptor blockade increases cortical DA release via 5-HT (1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J Neurochem 76:1521-1531. (Pubitemid 32198256)
36. Idris NF, Repeto P, Neill JC, Large CH (2005). Investigation of the effects of lamotrigine and clozapine in improving reversal-learning impairments induced by acute phencyclidine and D-amphetamine in the rat. Psychopharmacology (Berl) 179:336-348.
37. Javitt DC, Zukin SR (1991). Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148:1301-1308.
38. Jentsch JD, Roth RH (1999). The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 20:201-225. (Pubitemid 29067401)
39. Kargieman L, Santana N, Mengod G, Celada P, Artigas F (2007). Antipsychotic drugs reverse the disruption in prefrontal cortex function produced by NMDA receptor blockade with phencyclidine. Proc Natl Acad Sci USA 104:14843-14848. (Pubitemid 350003230)
40. Kargieman L, Santana N, Mengod G, Celada P, Artigas F (2008). NMDA antagonist and antipsychotic actions in cortico-subcortical circuits. Neurotoxicol Res 14:129-140.
41. Kroeze WK et al (2003). H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 28:519-526.
42. Krystal JH, D'Souza DC, Mathalon D, Perry E, Belger A, Hoffman R (2003). NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development. Psychopharmacology (Berl) 169:215-233. (Pubitemid 37264943)
43. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD et al (1994). Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans-psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 51:199-214. (Pubitemid 24081509)
44. Kwon JS, O'Donnell BF, Wallenstein GV, Greene RW, Hirayasu Y, Nestor PG et al (1999). Gamma frequency-range abnormalities to auditory stimulation in schizophrenia. Arch Gen Psychiatry 56:1001-1005. (Pubitemid 29526383)
45. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM (2009a). Second-generation vs first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 373:31-41.
46. Leucht S, Komossa K, Rummel-Kluge C, Corves C, Hunger H, Schmid F et al (2009b). A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry 166:152-163.
47. Lewis BL, O'Donnell P (2000). Ventral tegmental area afferents to the prefrontal cortex maintain membrane potential 'up' states in pyramidal neurons via D (1) dopamine receptors. Cereb Cortex 10:1168-1175.
48. Lewis DA, Anderson SA (1995). The functional architecture of the prefrontal cortex and schizophrenia. Psychol Med 25:887-894.
49. Lewis DA, Hashimoto T, Volk DW (2005). Cortical inhibitory neurons and schizophrenia. Nat Rev Neurosci 6:312-324. (Pubitemid 40469985)
50. Lewis DA, Lieberman JA (2000). Catching up on schizophrenia: natural history and neurobiology. Neuron 28:325-334.
51. Li Z, Prus AJ, Dai J, Meltzer HY (2009). Differential effects of M1 and 5-hydroxytryptamine1A receptors on atypical antipsychotic drug-induced dopamine efflux in the medial prefrontal cortex. J Pharmacol Exp Ther 330:948-955.
52. Lipina T, Labrie V, Weiner I, Roder J (2005). Modulators of the glycine site on NMDA receptors, D-serine and ALX 5407, display similar beneficial effects to clozapine in mouse models of schizophrenia. Psychopharmacology (Berl) 179:54-67. (Pubitemid 40576692)
53. Luby ED, Cohen D, Rosenbaum G, Gottlieb J, Kelley R (1959). Study of a new schizophrenomimetic drug: sernyl. AMA Arch Neurol Psychiatry 81:363-369.
54. Malhotra AK, Pinals DA, Adler CM, Elman I, Clifton A, Pickar D et al (1997). Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychopharmacology 17:141-150. (Pubitemid 27365955)
55. Marek GJ, Aghajanian GK (1999). 5-HT2A receptor or alpha1-adrenoceptor activation induces excitatory postsynaptic currents in layer V pyramidal cells of the medial prefrontal cortex. Eur J Pharmacol 367:197-206. (Pubitemid 29106371)
56. Marshall L, Helgadottir H, Molle M, Born J (2006). Boosting slow oscillations during sleep potentiates memory. Nature 444:610-613. (Pubitemid 44864437)
57. Meltzer HY (1999). The role of serotonin in antipsychotic drug action. Neuropsychopharmacology 21:106S-115S. (Pubitemid 29396478)
58. Miller EK, Cohen JD (2001). An integrative theory of prefrontal cortex function. Annu Rev Neurosci 24:167-202. (Pubitemid 32695227)
59. Mukovski M, Chauvette S, Timofeev I, Volgushev M (2007). Detection of active and silent states in neocortical neurons from the field potential signal during slow-wave sleep. Cereb Cortex 17:400-414. (Pubitemid 46052778)
60. Mutlu O, Ulak G, Celikyurt IK, Akar FY, Erden F (2011). Effects of olanzapine, sertindole and clozapine on learning and memory in the Morris water maze test in naive and MK-801-treated mice. Pharmacol Biochem Behav 98:398-404.
61. Newcomer JW, Farber NB, Jevtovic-Todorovic V, Selke G, Melson AK, Hershey T et al (1999). Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis. Neuropsychopharmacology 20:106-118. (Pubitemid 29010370)
62. Newman-Tancredi A (2010). The importance of 5-HT1A receptor agonism in antipsychotic drug action: rationale and perspectives. Curr Opin Invest Drugs 11:802-812.
63. O'Donnell P, Grace AA (1995). Synaptic interactions among excitatory afferents to nucleus accumbens neurons: hippocampal gating of prefrontal cortical input. J Neurosci 15:3622-3639.
64. Parks CL, Robinson PS, Sibille E, Shenk T, Toth M (1998). Increased anxiety of mice lacking the serotonin1A receptor. Proc Natl Acad Sci USA 95:10734-10739.
65. Pompeiano M, Palacios JM, Mengod G (1992). Distribution and cellular localization of mRNA coding for 5-HT1A receptor in the rat brain: correlation with receptor binding. J Neurosci 12:440-453.
66. Pompeiano M, Palacios JM, Mengod G (1994). Distribution of the serotonin 5-HT2 receptor family mRNAs: comparison between 5-HT2A and 5-HT2C receptors. Brain Res Mol Brain Res 23:163-178.
67. Popa D, Léna C, Fabre V, Prenat C, Gingrich J, Escourrou P, Hamon M et al (2005). Contribution of 5-HT2 receptor subtypes to sleep-wakefulness and respiratory control, and functional adaptations in knock-out mice lacking 5-HT2A receptors. J Neurosci 25:11231-11238. (Pubitemid 43083697)
68. Pradhan SN (1984). Phencyclidine (PCP): some human studies. Neurosci Biobehav Rev 8:493-501. (Pubitemid 15155160)
69. Puig MV, Artigas F, Celada P (2005). Modulation of the activity of pyramidal neurons in rat prefrontal cortex by raphe stimulation in vivo: involvement of serotonin and GABA. Cereb Cortex 15:1-14. (Pubitemid 40019048)
70. Rollema H, Lu Y, Schmidt AW, Sprouse JS, Zorn SH (2000). 5-HT (1A) receptor activation contributes to ziprasidone-induced dopamine release in the rat prefrontal cortex. Biol Psychiatry 48:229-237. (Pubitemid 30618995)
71. Rollema H, Lu Y, Schmidt AW, Zorn SH (1997). Clozapine increases dopamine release in prefrontal cortex by 5-HT1A receptor activation. Eur J Pharmacol 338:R3-R5. (Pubitemid 27507749)
72. Roth BL, Sheffler DJ, Kroeze WK (2004). Magic shotguns vs magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat Rev Drug Discov 3:353-359. (Pubitemid 38499762)
73. Sanchez-Vives MV, McCormick DA (2000). Cellular and network mechanisms of rhythmic recurrent activity in neocortex. Nat Neurosci 3:1027-1034.
74. Santana N, Bortolozzi A, Serrats J, Mengod G, Artigas F (2004). Expression of serotonin1A and serotonin2A receptors in pyramidal and GABAergic neurons of the rat prefrontal cortex. Cereb Cortex 14:1100-1109. (Pubitemid 39258165)
75. Santana N, Troyano-Rodriguez E, Mengod G, Celada P, Artigas F (2011). Activation of thalamocortical networks by the N-methyl-D-aspartate receptor antagonist phencyclidine: reversal by clozapine. Biol Psychiatry 69:918-927.
76. Schroeder CE, Lakatos P (2009). Low-frequency neuronal oscillations as instruments of sensory selection. Trends Neurosci 32:9-18.
77. Scorza MC, Castane A, Bortolozzi A, Artigas F (2010). Clozapine does not require 5-HT1A receptors to block the locomotor hyperactivity induced by MK-801 Clz and MK-801 in KO1A mice. Neuropharmacology 59:112-120.
78. Selemon LD, Goldman-Rakic PS (1999). The reduced neuropil hypothesis: a circuit based model of schizophrenia. Biol Psychiatry 45:17-25. (Pubitemid 29049200)
79. Shin YW, Krishnan G, Hetrick WP, Brenner CA, Shekhar A, Malloy FW et al (2010). Increased temporal variability of auditory event-related potentials in schizophrenia and Schizotypal Personality Disorder. Schizophr Res 124:110-118.
80. Shoham S, Nagarajan S (2003). The theory of central nervous system recording. In: Horch KW, Dhillon GS (eds). Neuroprosthetics: Theory and Practice. World Scientific Publishing: Singapore. pp 448-465.
81. Shu Y, Hasenstaub A, McCormick DA (2003). Turning on and off recurrent balanced cortical activity. Nature 423:288-293. (Pubitemid 40852698)
82. Spencer KM, Nestor PG, Niznikiewicz MA, Salisbury DF, Shenton ME, McCarley RW (2003). Abnormal neural synchrony in schizophrenia. J Neurosci 23:7407-7411. (Pubitemid 36999532)
83. Stefani MR, Moghaddam B (2005). Transient N-methyl-D-aspartate receptor blockade in early development causes lasting cognitive deficits relevant to schizophrenia. Biol Psychiatry 57:433-436. (Pubitemid 40215775)
84. Steinpreis RE (1996). The behavioral and neurochemical effects of phencyclidine in humans and animals: some implications for modeling psychosis. Behav Brain Res 74:45-55. (Pubitemid 26060022)
85. Steriade M, McCormick DA, Sejnowski TJ (1993a). Thalamocortical oscillations in the sleeping and aroused brain. Science 262:679-685. (Pubitemid 23350685)
86. Steriade M, Nunez A, Amzica F (1993b). A novel slow (>1 Hz) oscillation of neocortical neurons in vivo: depolarizing and hyperpolarizing components. J Neurosci 13:3252-3265. (Pubitemid 23241166)
87. Stickgold R (2005). Sleep-dependent memory consolidation. Nature 437:1272-1278. (Pubitemid 41568667)
88. Timofeev I, Grenier F, Bazhenov M, Sejnowski TJ, Steriade M (2000a). Origin of slow cortical oscillations in deafferented cortical slabs. Cereb Cortex 10:1185-1199.
89. Timofeev I, Grenier F, Steriade M (2000b). Impact of intrinsic properties and synaptic factors on the activity of neocortical networks in vivo. J Physiol (Paris) 94:343-355. (Pubitemid 32110919)
90. Tseng KY, Mallet N, Toreson KL, Le Moine C, Gonon F, O'Donnell P (2006). Excitatory response of prefrontal cortical fast-spiking interneurons to ventral tegmental area stimulation in vivo. Synapse 59:412-417.
91. Uhlhaas PJ, Singer W (2006). Neural synchrony in brain disorders: relevance for cognitive dysfunctions and pathophysiology. Neuron 52:155-168. (Pubitemid 44466360)
92. Uhlhaas PJ, Singer W (2010). Abnormal neural oscillations and synchrony in schizophrenia. Nat Rev Neurosci 11:100-113.
93. Verma A, Moghaddam B (1996). NMDA receptor antagonists impair prefrontal cortex function as assessed via spatial delayed alternation performance in rats: modulation by dopamine. J Neurosci 16:373-379. (Pubitemid 26010723)
94. Vollenweider FX, Kometer M (2010). The neurobiology of psychedelic drugs: implications for the treatment of mood disorders. Nat Rev Neurosci 11:642-651.
95. Weisstaub NV, Zhou M, Lira A, Lambe E, González-Maeso J, Hornung JP et al (2006). Cortical 5-HT2A receptor signaling modulates anxiety-like behaviors in mice. Science 313:536-540. (Pubitemid 44148461)
96. Winterer G, Coppola R, Goldberg TE, Egan MF, Jones DW, Sanchez CE et al (2004). Prefrontal broadband noise, working memory, and genetic risk for schizophrenia. Am J Psychiatry 161:490-500. (Pubitemid 38326104)
97. Yadav PN, Abbas AI, Farrell MS, Setola V, Sciaky N, Huang XP et al (2011). The presynaptic component of the serotonergic system is required for clozapine's efficacy. Neuropsychopharmacology 36:638-651.